Autophagy modulators - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Autophagy modulators The report assesses ...
January 2022
60 pages
B-Cell Activating Factor (BAFF) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “B-Cell Activating Factor (BAFF) Inhibitor The report ...
January 2022
60 pages
Bcl-xL Protein Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Bcl-xL Protein Inhibitor The report assesses ...
January 2022
60 pages
Bcr-Abl Tyrosine Kinase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Bcr-Abl Tyrosine Kinase Inhibitor The report ...
January 2022
60 pages
Benzodiazepine Receptor Agonist - Pipeline Insight, 2022
US$ 2,000.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Benzodiazepine Receptor Agonist The report assesses ...
January 2022
120 pages
Beta Receptor Agonist - Pipeline Insight, 2022
US$ 2,000.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Beta Receptor Agonist The report assesses the active Beta Receptor ...
January 2022
120 pages
Beta Receptor Antagonist - Pipeline Insight, 2022
US$ 1,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Beta Receptor Antagonist The report assesses ...
January 2022
90 pages
Beta Secretase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Beta Secretase Inhibitor The report assesses ...
January 2022
60 pages
Beta Selective Thyroid Hormone Receptor Agonist - Pipeline Insight, 2022
US$ 1,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Beta Selective Thyroid Hormone Receptor Agonist The ...
January 2022
60 pages
Beta-1 Receptors Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Beta-1 Receptors Antagonist The report assesses ...
January 2022
60 pages
Beta-1 Receptors Agonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Beta-1 Receptors Agonist The report assesses ...
January 2022
60 pages
Beta-2 Receptors Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Beta-2 Receptors Antagonist The report assesses ...
January 2022
60 pages
Beta-2 Receptors Agonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Beta-2 Receptors Agonist The report assesses ...
January 2022
60 pages
Beta-3 Receptors Agonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Beta-3 Receptors Agonist The report assesses ...
January 2022
60 pages
Beta-Lactamase Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Beta-Lactamase Inhibitor The report assesses ...
January 2022
60 pages
Blood Coagulation Factor Activators - Pipeline Insight, 2022
US$ 1,500.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Blood Coagulation Factor Activators The report assesses the active ...
January 2022
90 pages
Bradykinin Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Bradykinin Antagonist The report assesses ...
January 2022
60 pages
Bradykinin Receptor B1 Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Bradykinin Receptor B1 Antagonist The report ...
January 2022
60 pages
Bradykinin Receptor B2 Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Bradykinin Receptor B2 Antagonist The report ...
January 2022
60 pages
BRAFV600 mutation (B-Raf proto-oncogene, serine/threonine kinase) Inhibiotors - Pipeline Insight, 2022
US$ 1,500.00
... , product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “BRAFV600 mutation (B-Raf proto-oncogene, serine/threonine kinase) Inhibiotors The ...
January 2022
90 pages
Broad Spectrum Chemokine Inhibitor (BSCIs) - Pipeline Insight, 2022
US$ 1,500.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Broad Spectrum Chemokine Inhibitor (BSCIs) The report ...
January 2022
90 pages
Brutons Tyrosine Kinase (BTK) Inhibitors - Pipeline Insight, 2022
US$ 2,000.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Brutons Tyrosine Kinase (Btk) Inhibitor The report ...
January 2022
100 pages
C1 Esterase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “C1 Esterase Inhibitor The report assesses ...
January 2022
60 pages
C5a Receptor Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “C5a Receptor Antagonist The report assesses the active C5a Receptor ...
January 2022
60 pages
Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Calcitonin Gene-Related Peptide Receptor (CRLR) Antagonist The ...
January 2022
60 pages
Cannabinoid Agonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cannabinoid Agonist The report assesses ...
January 2022
60 pages
Cannabinoid Receptor Type 1 (CB1) Agonist - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cannabinoid Receptor Type 1 (CB1) Agonist The report ...
January 2022
60 pages
Cannabinoid Receptor Type 1 (CB1) Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cannabinoid Receptor Type 1 (CB1) Antagonist The report ...
January 2022
60 pages
Cannabinoid Receptor Type 2 (CB2) Agonist - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cannabinoid Receptor Type 2 (CB2) Agonist The report ...
January 2022
60 pages
Carbonic Anhydrase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Carbonic Anhydrase Inhibitor The report assesses ...
January 2022
60 pages
Carnitine Palmitoyltransferase I (CPT 1) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Carnitine Palmitoyltransferase I (CPT 1) Inhibitor The ...
January 2022
60 pages
Casein Kinase 2 Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Casein Kinase 2 Inhibitor The report assesses ...
January 2022
60 pages
Caspase 3 (CPP32, Apopain or YAMA) Activators - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Caspase 3 (CPP32, Apopain or YAMA) Activators The ...
January 2022
60 pages
Caspases Activators - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Caspases Activators The report assesses the active Caspases ...
January 2022
60 pages
Caspases Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Caspases Inhibitor ...
January 2022
60 pages
Catechol-O-methyltransferase (COMT) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Catechol-O-methyltransferase (COMT) Inhibitor The ...
January 2022
60 pages
Cathepsin K/S Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cathepsin K/S Inhibitor The report assesses ...
January 2022
60 pages
Cathepsin K Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cathepsin K Inhibitor The report assesses ...
January 2022
60 pages
Cathepsin S inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Cathepsin S inhibitor The report assesses ...
January 2022
60 pages
CCR Inhibitor - Pipeline Insight, 2022
US$ 2,000.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “CCR Inhibitor The report assesses the active CCR Inhibitor pipeline ...
January 2022
120 pages
CCR1 Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “CCR1 Inhibitor The report assesses the active CCR1 Inhibitor ...
January 2022
60 pages
CCR2 Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “CCR2 Inhibitor The report assesses the active CCR2 Inhibitor ...
January 2022
90 pages
CCR3 Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “CCR3 Inhibitor The report assesses the active CCR3 Inhibitor ...
January 2022
60 pages
CCR4 Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “CCR4 Inhibitor The report assesses the active CCR4 Inhibitor ...
January 2022
60 pages
CCR5 Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “CCR5 Inhibitor The report assesses the active CCR5 Inhibitor ...
January 2022
60 pages
CD (Cluster of Differentiation) Inhibitor - Pipeline Insight, 2022
US$ 2,000.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “CD (Cluster of Differentiation) Inhibitor The report ...
January 2022
120 pages
CD 19 Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... 19 Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent ...
January 2022
60 pages
CD 3 Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... 3 Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent ...
January 2022
90 pages
CD 33 Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... 33 Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent ...
January 2022
60 pages
CD 40 Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... 40 Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent ...
January 2022
60 pages
